Therapeutic antibodies targeting ITPRIPL1 can effectively enhance the cytotoxicity of tumor-specific T cells and achieve tumor growth control and are expected to be promising therapeutic targets for various types of tumors [213]. This evidence concerns the gene ITPRIPL1 and neoplasm.